NCT00213083View on ClinicalTrials.gov

Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission

PHASE3CompletedINTERVENTIONAL
Enrollment

6,203

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
HIV InfectionsAIDSSexually Transmitted DiseasesHIV Seroconversion
Interventions
DRUG

Carraguard (PC-515)

Trial Locations (3)

4067

Isipingo Clinic, Overport

7925

Empilisweni Clinic, Cape Town

0204

Setshaba Research Clinic, University of Limpopo - Medunsa Campus, Medunsa

All Listed Sponsors
collaborator

United States Agency for International Development (USAID)

FED

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Population Council

OTHER

NCT00213083 - Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission | Biotech Hunter | Biotech Hunter